Long-Term Outcome of Repeat Microvascular Decompression for Hemifacial Spasm

Xu, Xiao; Zhen, Xueke; Yue, Yuan; Liu, Hongju; Liu, Jiang; Xu, Jun; Li, Xiubin; Zhang, Li; Yu, Yanying

doi:10.1016/j.wneu.2017.11.144

Cited by 19 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hemifacial spasm (HFS) is a common cranial nerve disease characterized by irregular, involuntary, and recurring spasms of the facial muscles innervated by the ipsilateral seventh cranial nerve. [1][2][3] It is generally believed that HFS is caused by cross-compression of the facial nerve by the offending vessel at the root exit zone (REZ). 4 Accordingly, microvascular decompression (MVD) has become widely accepted as the first-line therapeutic option for HFS, with reports of immediate cure rates ranging from 50% to 98%.…”

Section: Introductionmentioning

confidence: 99%

Long-term Outcomes of Microvascular Decompression in the Treatment of Hemifacial Spasm Based on Different Offending Vessels

Zhao

Tang

Zhang

et al. 2019

J Neurol Surg A Cent Eur Neurosurg

View full text Add to dashboard Cite

Objective To evaluate clinical features, outcomes, and complications in patients with hemifacial spasm (HFS) after microvascular decompression (MVD) of different offending vessels. Methods Clinical data were collected from 362 patients with HFS treated with MVD between January 2013 and January 2014. Patients were divided into five groups based on the offending vessel: A (anterior inferior cerebellar artery [AICA] compression), B (posterior inferior cerebellar artery [PICA] compression), C (AICA plus PICA compression), D (vertebral artery [VA] compression), and E (VA plus small vessel compression). Results The most common offending vessel was the AICA (51.38%). The most common compression site was the root exit zone. During the follow-up period, the effective rate was 95.48% in group A, 92.15% in group B, 93.10% in group C, 90.14% in group D, and 91.45% in group E. Twenty-nine patients exhibited delayed facial palsy, the most common complication. Conclusion No statistically significant differences were found in long-term outcomes or MVD-related complications among the study groups. The type of offending vessel was not a prognostic factor for MVD in patients with HFS.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term Outcomes of Microvascular Decompression in the Treatment of Hemifacial Spasm Based on Different Offending Vessels

Zhao

Tang

Zhang

et al. 2019

J Neurol Surg A Cent Eur Neurosurg

View full text Add to dashboard Cite

show abstract

“…For the quality-of-life aspect, most microvascular decompression studies report only short term, postoperative and one-year improvement of disease-specific QoL. The authors of [11,12] reported that 24.1% of re-operated microvascular decompression surgery patient have complications such as hearing loss and facial paresis, which have highly negative impacts on quality of life. Based on the updated evidence, this study reports long-term disease-specific QoL improvement without serious complications.…”

Section: Discussionmentioning

confidence: 99%

The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A

Kongsaengdao

Maneeton

2021

Toxins

View full text Add to dashboard Cite

This study aimed to determine the long-term quality of life (QoL) in hemifacial spasm (HFS) patients after treating with Abo-botulinum toxin A (Abo-BTX). The study assessed the disease-specific QoL (hemifacial spasm questionnaire 30 items; HFS 30), the involuntary movements (abnormal involuntary movement scale; AIMS), general health QoL (Medical Outcomes 36-Item Short Form Health Survey; SF-36), and Depression (the Center of Epidemiologic Studies-Depression questionnaire; CES-D). A total of 74 HFS patients were enrolled from 2012 to 2017. The disease-specific QoL; involuntary movements; and the general health domain of SF 36 were significantly improved after injections of Abo-BTX A in the first few years (p < 0.04), but significantly decreased at the fifth year of treatment without significant clinical resistance observed (p < 0.001). Only the general health domain of SF 36 showed persistent improvement over five years (p = 0.02). In summary, Abo-BTX A can improved quality of life in the first few years; however only the general health domain of SF-36 showed significant improvement over five years (p = 0.02). No clinical resistance was observed.

show abstract

“…At a follow-up of 1 year, 20 patients were improved, with one facial nerve palsy secondary to surgery. Xu et al [16] reported on 42 patients with persistent HS and 36 cases of recurrent HS out of a population of 1200 cases of MVD for HS. e period to recurrence ranged from 0.1 to 5 years, with an average interval of 1.4 years.…”

Section: Discussionmentioning

confidence: 99%

Case report of recurrent hemifacial spasm attributed to over-impaction with Teflon sponge

Seaman¹,

Noeller²,

Nourski³

et al. 2020

Surgical Neurology International

View full text Add to dashboard Cite

Background: Hemifacial spasm (HS) is a muscular disorder frequently exacerbated by arterial compression amenable to surgical intervention through microvascular decompression (MVD). Recurrence is a known cause and warrants investigation. Case Description: A 65-year-old woman presented with the left HS of 7 years duration. Her symptoms were initially well controlled with botulinum toxin injections. However, these injections eventually lost their effectiveness, necessitating MVD. At surgery, the anterior inferior cerebellar artery was indenting the facial nerve at its root entry zone. This was carefully dissected away, and several Teflon (polytetrafluoroethylene) felt pledgets were used for decompression. Postoperatively, the patient reported great improvement of her symptoms for 3 months. Gradually her spasms returned, intermittently at first, until finally they became persistent 6 months postoperatively. An MRI was obtained showing elevation and posterior displacement of the VII-VIII complex by the pledgets. After failing to improve, the patient opted for reoperation 10 months after initial MVD. At surgery, the Teflon pledgets were displacing the VII-III nerves posteriorly and superiorly. The Teflon pledgets were dissected free, and the nerve dis-impacted. On her postoperative visit 1 year later, she is spasm free, subjectively, and objectively. Conclusion: This case illustrates the value of re-imaging recurrent HS, and re-exploration with a favorable rkesult.

show abstract

Long-Term Outcome of Repeat Microvascular Decompression for Hemifacial Spasm

Cited by 19 publications

References 15 publications

Long-term Outcomes of Microvascular Decompression in the Treatment of Hemifacial Spasm Based on Different Offending Vessels

Long-term Outcomes of Microvascular Decompression in the Treatment of Hemifacial Spasm Based on Different Offending Vessels

The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A

Case report of recurrent hemifacial spasm attributed to over-impaction with Teflon sponge

Contact Info

Product

Resources

About